Please use this identifier to cite or link to this item: http://ahro.austin.org.au/austinjspui/handle/1/22109
Title: Moderate alcohol use in fatty liver disease; don't throw the cabernet out with the bathwater.
Authors: Gow, Paul J;Testro, Adam G;Hey, Penelope;Sinclair, Marie
Affiliation: Victorian Liver Transplant Unit, Austin Health, Heidelberg, Victoria, Australia
The University of Melbourne, Victoria, Australia
Issue Date: 29-Nov-2019
EDate: 2019-11-29
Citation: Hepatology (Baltimore, Md.) 2019; online first: 29 November
Abstract: We congratulate Dr Aberg and colleagues for a significant contribution to the literature on the important topic of moderate alcohol use in fatty liver disease (NAFLD) (1). Approximately 30% of the population of the Western world has obesity and/or other complications of insulin resistance and the metabolic syndrome. Due to the magnitude of this problem worldwide, palatable lifestyle therapies that are affordable, available and acceptable are necessary to curtail preventable early deaths. Moderate alcohol has the potential to fill this space, although knowledge remains limited.
URI: http://ahro.austin.org.au/austinjspui/handle/1/22109
DOI: 10.1002/hep.31049
PubMed URL: 31782819
Type: Letter
Subjects: NAFLD
cardiovascular disease
fibrosis
mortality
wine
Appears in Collections:Journal articles

Files in This Item:
There are no files associated with this item.


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.